Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group

被引：4

作者：

Dipasquale, Valeria ^{[1
]}

Martinelli, Massimo ^{[2
]}

Aloi, Marina ^{[3
]}

Accomando, Salvatore ^{[4
]}

Alvisi, Patrizia ^{[5
]}

Arrigo, Serena ^{[6
]}

Banzato, Claudia ^{[7
]}

Bramuzzo, Matteo ^{[8
]}

Cananzi, Mara ^{[9
]}

Corpino, Mara ^{[10
]}

Di Mari, Clelia ^{[11
]}

Di Nardo, Giovanni ^{[12
]}

Dilillo, Anna ^{[13
]}

Dodaro, Natale ^{[14
]}

Felici, Enrico ^{[15
]}

Gatti, Simona ^{[16
]}

Graziano, Francesco ^{[17
]}

Illiceto, Maria Teresa ^{[18
]}

Norsa, Lorenzo ^{[19
]}

Opramolla, Anna ^{[20
]}

Pastore, Maria ^{[21
]}

Pavanello, Paolo Maria ^{[22
]}

Romeo, Erminia ^{[23
]}

Scarallo, Luca ^{[24
]}

Strisciuglio, Caterina ^{[25
]}

Zuin, Giovanna ^{[26
]}

Romano, Claudio ^{[1
]}

机构：

[1] Univ Messina, G Martino Univ Hosp, Dept Human Pathol Adulthood & Childhood G Barresi, Pediat Gastroenterol & Cyst Fibrosis Unit, Via Consolare Valeria, I-98124 Messina, Italy

[2] Univ Naples Federico II, Dept Translat Med Sci, Sect Pediat, Naples, Italy

[3] Sapienza Univ, Dept Maternal & Child Hlth, Pediat Gastroenterol Unit, Umberto I Hosp, Rome, Italy

[4] Univ Palermo, Promise Dept, Pediat Operat Unit, Palermo, Italy

[5] Maggiore Hosp, Pediat Gastroenterol Unit, Bologna, Italy

[6] IRCCS Giannina Gaslini Childrens Hosp, Unit Pediat Gastroenterol & Endoscopy, Genoa, Italy

[7] Univ Hosp Verona, Dept Surg Sci Dent Gynecol & Pediat, Pediat Clin, Verona, Italy

[8] IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, Italy

[9] Univ Hosp Padova, Dept Womens & Childrens Hlth, Unit Digest Endoscopy Hepatol & Care Child Liver, Pediat Gastroenterol, Padua, Italy

[10] AOB, Pediat Gastroenterol Unit, Microcitem Hosp, Pediat Clin, Cagliari, Italy

[11] Univ Milan, V Buzzi Childrens Hosp, Pediat Clin, Milan, Italy

[12] Sapienza Univ Rome, St Andrea Univ Hosp, Fac Sch Med & Psychol, NESMOS Dept,Pediat Gastroenterol & Endoscopy Unit, Rome, Italy

[13] Sapienza Univ Rome, Santa Maria Goretti Hosp, Maternal & Child Hlth Dept, Latina, Italy

[14] Hosp Cosenza, Pediat Unit, Cosenza, Italy

[15] AO SS Antonio & Biagio & C Arrigo, Ctr Digest Dis, Pediat & Pediat Emergency Unit, Childrens Hosp,U Bosio, Alessandria, Italy

[16] G Salesi Childrens Hosp, Dept Pediat, Ancona, Italy

[17] Villa Sofia Cervello Hosp, Pediat Unit, Palermo, Italy

[18] Santo Spirito Hosp, Dept Pediat, Pediat Gastroenterol & Endoscop Unit, Pescara, Italy

[19] Papa Giovanni XXIII Hosp, Pediat Gastroenterol & Transplantat, Bergamo, Italy

[20] Univ Turin, Azienda Osped Univ Citta Salute & Sci, Regina Margherita Childrens Hosp, Pediat Gastroenterol Unit, Turin, Italy

[21] IRCCS Casa Sollievo Sofferenza, Div Pediat, Foggia, Italy

[22] Reg Hosp Ca Foncello, Dept Pediat, Treviso, Italy

[23] Bambino Gesu Pediat Hosp, Digest Surg & Endoscopy Unit, Rome, Italy

[24] Meyer Childrens Hosp, Unit Gastroenterol & Nutr, Florence, Italy

[25] Luigi Vanvitelli Univ Campania, Dept Woman Child & Gen & Specialist Surg, Naples, Italy

[26] Univ Milano Bicocca, San Gerardo Hosp, Fdn MBBM, Pediat Dept, Monza, Italy

来源：

PEDIATRIC DRUGS | 2022年 / 24卷 / 01期

关键词：

EUROPEAN CROHNS; ITALIAN GROUP; KNOWLEDGE; MEMBERS;

D O I：

10.1007/s40272-021-00486-8

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Objective The aim was to assess the awareness and real-life use of biosimilars in inflammatory bowel disease (IBD) among the members of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Methods An anonymous web survey involving all SIGENP IBD units which can prescribe biosimilars was conducted between July 1st and December 1st, 2020. The questionnaire included 18 questions addressing the most relevant aspects of biosimilars in pediatric IBD, i.e., advantages, disadvantages, costs, traceability, general knowledge, and real-life use. A descriptive analysis of responses was performed. Results Responses came from 26 pediatric IBD units in Italy, with representation of the North, the Center, and the South of Italy. The majority of participants (n = 20) had spent > 10 years caring for pediatric IBD patients, and worked in a center which had between 100 and 500 registered pediatric IBD patients (n = 14). Most participants (n = 18) reported they were aware that biosimilars have similar efficacy and safety to those of the originator, and all regarded cost-sparing as the main advantage of biosimilars. Most respondents (n = 20) reported they switch from originator to biosimilar in their everyday clinical practice, mostly during the maintenance phase. Most respondents (n = 20) registered no acute adverse events. Nearly all participants felt totally or very confident in using biosimilars. Conclusions A few years after the introduction of the first biosimilar into the market, real-life data coming from the major IBD units in Italy confirm a favorable and confident position on the use of biosimilars in pediatric IBD.

引用

页码：57 / 62

页数：6

共 41 条

[31] Real-world quality of life experience of subcutaneous infliximab use in children with Inflammatory Bowel Disease (IBD) at a tertiary paediatric centre
Dutt, S.
Chidgey, T.
Chuah, C. W.
Eldredge, J.
Magoffin, A.
Puppi, J.
Siew, S.
Singh, N.
Stormon, M.
Tano, M.
Thacker, K.
O'Loughlin, E. V.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2163 - i2163
[32] REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD)
Pugliese, D.
Rogai, F.
Variola, A.
Viola, A.
Privitera, A. C.
Allocca, M.
Bossa, F.
Cappello, M.
Lorenzon, G.
Mazzuoli, S.
Principi, M. B.
Sablich, R.
Ferronato, A.
Festa, S.
Moser, L.
Tapete, G.
Bodini, G.
Di Girolamo, M.
Grossi, L.
Mocci, G.
Mocciaro, F.
Ricci, C.
Saibeni, S.
Spagnuolo, R.
Cortelezzi, C. C.
Orlandini, B.
Capoferro, E.
Costantino, G.
Armuzzi, A.
DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E136 - E136
[33] Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
Tarsi, Antonio
Mocci, Giammarco
Cuomo, Antonio
Ferronato, Antonio
Elisei, Walter
Picchio, Marcello
Maconi, Giovanni
Scaldaferri, Franco
Papa, Alfredo
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2022, 31 (04) : 411 - 416
[34] The influence of anxiety and depression and the online mindfulness interventions on the quality of life among patients with Inflammatory Bowel Disease (IBD) : Web-Based Survey Study
Hu, S.
Xu, D.
Zhu, C.
Wang, Y.
Li, S.
Chen, Y.
Chen, Y.
Wang, C.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1977 - I1977
[35] A propensity score-weighted comparison of vedolizumab and adalimumab in Crohn's disease: Real-life data from the Sicilian Network for inflammatory bowel disease (SN-IBD)
Macaluso, F. S.
Ventimiglia, M.
Fries, W.
Viola, A.
Sitibondo, A.
Cappello, M.
Scrivo, B.
Busacca, A.
Privitera, A. C.
Camilleri, S.
Garufi, S.
Di Mitri, R.
Mocciaro, F.
Belluardo, N.
Giangreco, E.
Bertolami, C.
Renna, S.
Orlando, R.
Rizzuto, G.
Cottone, M.
Orlando, A.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S316 - S316
[36] The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper
Fiorino, Gionata
Girolomoni, Giampiero
Lapadula, Giovanni
Orlando, Ambrogio
Danese, Silvio
Olivieri, Ignazio
AUTOIMMUNITY REVIEWS, 2014, 13 (07) : 751 - 755
[37] A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
Macaluso, F. S.
Ventimiglia, M.
Fries, W.
Viola, A.
Cappello, M.
Scrivo, B.
Magnano, A.
Pluchino, D.
Camilleri, S.
Garufi, S.
Di Mitri, R.
Mocciaro, F.
Magri, G.
Ferracane, C.
Citrano, M.
Graziano, F.
Bertolami, C.
Renna, S.
Orlando, R.
Rizzuto, G.
Cottone, M.
Orlando, A.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S561 - S561
[38] A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)
Macaluso, F. S.
Ventimiglia, M.
Fries, W.
Viola, A.
Cappello, M.
Scrivo, B.
Magnano, A.
Pluchino, D.
Camilleri, S.
Garufi, S.
Di Mitri, R.
Mocciaro, F.
Magri, G.
Ferracane, C.
Citrano, M.
Graziano, F.
Bertolami, C.
Renna, S.
Orlando, R.
Rizzuto, G.
Cottone, M.
Orlando, A.
DIGESTIVE AND LIVER DISEASE, 2020, 52 : S9 - S10
[39] Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting
Serena Pastore
Samuele Naviglio
Arianna Canuto
Loredana Lepore
Stefano Martelossi
Alessandro Ventura
Andrea Taddio
Pediatric Drugs, 2018, 20 : 165 - 171
[40] Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting
Pastore, Serena
Naviglio, Samuele
Canuto, Arianna
Lepore, Loredana
Martelossi, Stefano
Ventura, Alessandro
Taddio, Andrea
PEDIATRIC DRUGS, 2018, 20 (02) : 165 - 171

← 1 2 3 4 5 →